Raw, Andre S <br/><br/>
Regulatory considerations of pharmaceutical solid polymorphism in Abbreviated New Drug Applications (ANDAs).  [electronic resource] 

 -  Advanced drug delivery reviews  Feb 2004 
 - 397-414 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>0169-409X 
<br/><br/><label>Standard No.: </label>10.1016/j.addr.2003.10.011  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Biological Availability<br/>Carbamazepine--chemistry<br/>Cefuroxime--analogs & derivatives<br/>Chemistry Techniques, Analytical<br/>Crystallography<br/>Decision Trees<br/>Drug Approval--methods<br/>Drug Stability<br/>Drugs, Generic--chemistry<br/>Enalapril--chemistry<br/>Humans<br/>Molecular Conformation<br/>Phase Transition<br/>Prazosin--analogs & derivatives<br/>Quality Control<br/>Ranitidine--chemistry<br/>Solubility<br/>Sulfonamides--chemistry<br/>Technology, Pharmaceutical<br/>Therapeutic Equivalency<br/>Torsemide<br/>United States<br/>United States Food and Drug Administration<br/>Warfarin--chemistry